Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
MAD: Average Change from Baseline in Serum Iron Through Day 7 Figure 1 MAD: Average Change from Baseline in Transferrin...